You are here

AstraZeneca

J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant

Yahoo/Zacks.com

Wed, 11/22/23 - 11:38 am

non-small cell lung cancer

AstraZeneca’s Imfinzi Phase III trial raises trial design questions

Clinical Trials Arena

Tue, 11/21/23 - 11:41 am

clinical trials

Senate Democrats press Sanofi and AZ for answers as 'unprecedented' demand spurs shortage of RSV antibody Beyfortus

Fierce Pharma

Mon, 11/20/23 - 09:38 pm

The Next Generation of Weight Loss Drugs is Rapidly Approaching

BioSpace

Mon, 11/20/23 - 11:32 am

AZ launches digital clinical trials business

Pharmaphorum

Mon, 11/20/23 - 10:10 am

clinical trials

AstraZeneca’s AKT Inhibitor Wins FDA Approval for Combo Breast Cancer Treatment

BioSpace

Sun, 11/19/23 - 09:36 pm

FDA Approves Truqap Plus Faslodex for Advanced HR-Positive Breast Cancer

Pharm Exec

Fri, 11/17/23 - 10:09 am

AstraZeneca Bid to Expand Imfinzi’s NSCLC Label Hit with Phase III Flop

BioSpace

Tue, 11/14/23 - 10:55 am

clinical trials

non-small cell lung cancer

AstraZeneca’s Imfinzi meets PFS primary endpoint in Phase III HCC trial

Clinical Trials Arena

Fri, 11/10/23 - 10:06 am

clinical trials

hepatocellular carcinoma

AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drug

Fierce Biotech

Thu, 11/9/23 - 09:58 am

sickle cell disease

AbbVie, AstraZeneca, Boehringer and more face FTC's ire for 'improper' patent listings

Fierce Pharma

Tue, 11/7/23 - 11:08 pm

Boehringer Ingelheim

RSV is on the rise but preventative drugs are in short supply

MIT Technology Review

Mon, 11/6/23 - 10:04 am

AstraZeneca's failed cancer drug gets new lease on life thanks to positive kidney disease data

Fierce Biotech

Fri, 11/3/23 - 11:55 am

chronic kidney disease

HHS Challenges AstraZeneca’s Motion for Summary Judgement in IRA Lawsuit

BioSpace

Fri, 11/3/23 - 10:58 am

Inflation Reduction Act

Merck's Keytruda nabs FDA nod in biliary tract cancer, catching up with AstraZeneca's Imfinzi

Fierce Pharma

Wed, 11/1/23 - 10:10 pm

biliary tract cancer

AstraZeneca Drops $245M on Cell and Gene Therapies in Deal with Cellectis

BioSpace

Wed, 11/1/23 - 11:07 am

Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead

Fierce Biotech

Mon, 10/30/23 - 11:58 am

PARP inhibitors

Gilead Sciences

[podcast]AstraZeneca’s Arun Krishna says Tagrisso-based combo promises new option in lung cancer

Medical Marketing and Media

Thu, 10/26/23 - 10:37 am

ESMO: AstraZeneca aims for ‘2.0’ cancer pipeline, shares bispecific data

Fierce Biotech

Tue, 10/24/23 - 07:52 pm

AZ seeks FDA okay for first self-administered flu vaccine

Pharmaphorum

Tue, 10/24/23 - 10:03 am

FluMist Quadrivalent

self-administered vaccines

Pages